Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-92526-z
Abstract: Posttransplantation cyclophosphamide (PTCy) has become a popular option for haploidentical hematopoietic stem cell transplantation (HSCT). However, personalized methods to adjust immune intensity after PTCy for each patient’s condition have not been well studied. Here, we… read more here.
Keywords: reduced dose; ptcy; dose ptcy; gvl effect ... See more keywords
Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes
Sign Up to like & getrecommendations! Published in 2017 at "OncoImmunology"
DOI: 10.1080/2162402x.2017.1356152
Abstract: ABSTRACT Use of high-dose, post-transplant cyclophosphamide (PTCy) results in low rates of graft-versus-host-disease (GVHD) and favorable immune reconstitution, although with higher rates of relapse and somewhat high rates of graft failure. We hypothesized that permissible… read more here.
Keywords: low dose; ptcy; atg; dose ptcy ... See more keywords